Symposia 6 - The WHO System for Reporting Soft Tissue Cytopathology: The Rationale, Structure, Categories and Application in Routine Reporting
The WHO System for Reporting Soft Tissue Cytopathology has been developed and a book written and published by an expert editorial board of cytopathologists brought together by the WHO publisher IARC in a joint program with the International Academy of Cytology over the last eighteen months. The Reporting System is based on six well defined categories each of which will have a risk of malignancy and recommendation for further diagnostic management. The aim is to standardize the approach to reporting soft tissue cytopathology and improve communication with clinicians and ultimately improve patient care. The key diagnostic cytopathological features have been established by consensus for each lesion or neoplasm, and a discussion of the cytopathological differential diagnosis and the appropriate use of ancillary testing are presented.
This educational activity is designed for pathologists, cytopathologists, cytotechnologists, students and other members of the cytopathology community.
- Understand the rational, structure, categories and routine application of the 2022 WHO International System for Reporting Soft Tissue Cytopathology
- Understand how to apply the system to their routine reporting in soft tissue cytopathology
- Become aware that the consensus key diagnostic cytopathological features, with a discussion of the differential diagnosis based on the cytopathology features, is presented as a key component of the system, along with the appropriate use of ancillary testing in an integrated final diagnosis and report
Henryk A. Domanski, MD, PhD, MIAC
Ian Cree, FRCPath
Vickie Y. Jo, MD
Jerzy Klijanienko, MD, PhD, MIAC
Xiaohua Qian, MD
Bharat Rekhi, MD, DNB, MIAC, FRCPATH
Matthew Zarka, MD
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
The faculty, committee members, Executive Board and staff who are in position to control the content of this activity are required to disclose to the ASC and to learners any financial relationships that have occurred within the last 24 months with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The ASC has reviewed the disclosures and mitigated all relevant financial relationships.
The following individuals have reported financial relationships:
Michael Berry, SCT(ASCP)MBCM: Stockholder-Hologic
Oscar Lin, MD, PhD: Consultant – Hologic and Jansen
Liron Pantanowitz, MD: Consultant – Hamamatsu, Advisory Board for Ibex
Martha B. Pitman, MD, FIAC: Consultant – Adenocyte, LLC
Donna K. Russell, MEd, CT(ASCP), HT(ASCP): Advisory Board – Hologic Scientific
Christopher J. VandenBussche, MD, PhD: Ad hoc advisory board panel and Consultant – Roche
Paul VanderLaan, MD, PhD: Consultant – Gala Therapeutics
The following individuals have reported no relevant financial relationships:
Susan A. Alperstein, MS, CT(ASCP), Kristen A. Atkins, MD, Zubair, Baloch, MD, PhD, Guliz A. Barkan, MD, Christine N. Booth, MD, Leigh Ann Cahill, BS, CT(ASCP)CMIAC, Barbara A. Centeno, MD, Deborah J. Chute, MD, Amy C. Clayton, MD, Jacqueline M. Cuda, BS, SCT(ASCP), Fang Fan, MD, PhD, Kara L. Hansing, MEd, SCT(ASCP)CM, Aparna M Mahajan MD, Sara E. Monaco, MD, Michiya Nishino MD, PhD, N. Paul Ohori MD, Lynnette S. Pineault, MBA, SCT(ASCP), Sinchita Roy-Chowdhuri, MD, PhD, Momin T. Siddiqui, MD, FIAC, Z. Laura Tabatabai, MD, Sana O. Tabbara, MD, Michael J. Thrall, MD, Dena M. Tonkovich, BS, CT(ASCP), Dawn L. Underwood, MS, CT(ASCP), Vivian L. Weiss, MD, PhD, Teresa Wood, MPH, BA, CT(ASCP), Lisa Zhang, MD, Henryk A. Domanski, MD, PhD, MIAC, Ian Cree, FRCPath, Vickie Y. Jo, MD, Jerzy Klijanienko, MD, PhD, MIAC, Xiaohua Qian, MD, Bharat Rekhi, MD, DNB, MIAC, FRCPATH, Matthew Zarka, MD
The ASC staff associated with the development of content for this activity reported no relevant financial relationships.
Continuing Medical Education (CME) Statement
The American Society of Cytopathology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The American Society of Cytopathology designates this enduring educational activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
American Board of Pathology Maintenance of Certification (CC)
This product can help fulfill the CME requirements mandated by the American Board of Pathology Continuing Certification (CC) process. Earn up to 2.0 Credit Hours.
Continuing Medical Laboratory Education (CMLE)
The ASC designates this activity for a maximum of 2.0 Continuing Medical Laboratory Education (CMLE) credit hours for non-physicians. The CMLE credit hours meet the continuing education requirements for the ASCP Board of Registry Certification Maintenance Program. Participants should claim only the credit commensurate with the extent of their participation in the activity.
Cytotechnologists with Licenses in Florida and California
This program is approved for 2 continuing education credits in the States of Florida and California. The credit on each link is good for three years from the live presentation date.
- 2.00 AMA PRA Category 1 Credit™
- 2.00 California Credits
- 2.00 CMLE
- 2.00 Florida Credits
- 2.00 Participant